Avacta Share Discussion Threads

[fieldhouse] 26/3/2024 13:49

TW got it wrong with Tui !! doing well

[amanitaangelicus] 26/3/2024 08:14

Convi reset is the only game in town. Conveniently not being talked about by Smith. Did the convi boys get some extra 50p ers too? What s the play? Avoid until known. Something s afoot.

[ohwhatfun] 25/3/2024 21:30

👍 I thought Log had closed then gone long low 50’s for a bounce which seemed a mad decision given the plethora of 50p shares and no takers for those wanting quick profits.

Convi stock soon? It will be interesting to see what the conversion floor is. So much of the detail was never shared, just guesswork below 95p and some timelines where the goalposts move.

[stmcn] 25/3/2024 17:59

Low value share, low value debate… yawn …

[countbasie1] 25/3/2024 10:22

Oh what funYou close a short by buying. Basic stuff.

[jaknife] 25/3/2024 09:39

ohwhatfun,

Loglorry was short in the run up to the placing and bought AVCT on 29th Feb to close that short.

That Avacta needed to raise funds was obvious. Being short in the run up to the placing was the easiest trade of the year.

JakNife

[ohwhatfun] 25/3/2024 08:58

Loglorry

29th Feb you said

I bought AVCT today in fairly big size.

Not too long after you posted gloating about closing a massive short.

The long and short of it seems you simply make it up.

It seems the Avacta buzz has gone for now, with 10s of millions of shares held at 50p with holders hoping for buyers to take a profit on them.

Reality is there was not enough retail demand from existing holders, to take what Avacta offered.

Hence there no buyers to take stock from them.

No doubt the Myles pump pre raise soaked up those that had cash looking to get back in but were screwed in the FOMO game.

The CEO has a lot to answer for, the continual over-egging of a high risk investment.

[amanitaangelicus] 22/3/2024 13:47

Off you pop then. Attaboy.

[riskyinvestor] 22/3/2024 10:35

Tower Resources (TRP) is the Stock to be in

[ohwhatfun] 21/3/2024 20:29

Waffle, justifiably turned pancake.

[amanitaangelicus] 21/3/2024 18:01

Stu ...Smith is a typical Aim CEO ie promises much, delivers very little. Still, he has to go thro the Phase hoops, so I.m being unfair. He has to do this. Royal Marsden etc always doing expts on peeps, big revenue grabber. Smith will spin this out til 2025, wity other fluff, new AVAs. Then in 2025 we ll know. Hell of a wait , more raises too. Awful. The' pipeline ' is just fluffing material. One swallow might make a summer if the results on C survival are grand. Meanwhile Smith takes his juicy salary, and nears an early retirement. Aim- always the way. GLA ...the trapped, trainwrecked and traders. In the Time Lord we trust.

[pwhite73] 21/3/2024 16:45

FithyPoor - Of course it's a lie. Why do you think the share price is only 53p. Why is big Pharma not swooning all over this new drug discovery and where is the TR1 for the major European Health Care Fund.

[pwhite73] 21/3/2024 14:49

Raj b - "The danger to anyone else would not be acceptable."

The point is there is no danger to anybody because the Dox is not releasing anywhere, neither the healthy tissue or the tumours. That's why the Safety Committee has agreed to the larger dosage increases and the much shorter periods of time between dosages now down to two weeks.

Don't let them fool you they've been doing it for long enough.

[dalep716] 21/3/2024 14:35

The takeaways from today's RNS are, in my opinion, that all is progressing exceedingly well in the Avacta camp and that only a meaningful (large) deal will move the share price significantly. I'm expecting 5 percent today then steady small upward ticks until that first deal. I also expect explanation if not contrition from AS on the trashing of the SP, I hope not to be disappointed on that at least.

[rajraj b] 21/3/2024 14:22

Those not able to continue would likely have passed away through their cancer or any number of complications due to the terminal stages of their disease. But I'm sure that you can appreciate that not one was expected to live as long as this. That's the whole point of selecting these types of patients for this type of trial. The danger to anyone else would not be acceptable. Patients are not expecting to see signs of efficacy. None! Some are still alive and have been advised by the investigators ( together with their overseeing clinicians no doubt) to continue taking the drug. Why?

[stmcn] 21/3/2024 14:19

TBH - the RNS sounds just like another BS Smith ‘no news’ note. Pointless issuing it and just riles the LTH’s as Avacta seemingly unable to close out P1a and that continues to drag with no commitment on exit into P2. Needs a CEO change, as Smith cannot manage a plan and clearly cannot manage commercial deals/finances/investment and investors. Another grim week.

[1347] 21/3/2024 14:03

"A number of patients remain on the three-weekly study at this time in several different cohorts."

Fine and hopefully it's helping them, great if so, but how many out of the total and what happened to the others?

As has been said before, we need hard data on efficacy and we just aren't going to get it until the end of Phase 2, which is ages away, especially with Avacta. All we get are a few titbits here and there which can't be quantified and can be interpreted however you like.

[pwhite73] 21/3/2024 11:42

Raj b - "Also, if as you suggest, there is no evidence that AVA6000 is helping then why would these patients still be taking the drug?"

It is common practice in oncology that patients who doctors have diagnosed as terminally ill try out a number of experimental drugs or drugs at very early stages. Even drugs that have failed efficacy tests at various clinical stages can be deployed on terminally ill patients only. They are simply acting as guinea pigs for the medical service. It's no different from people who donate their organs to science after they die.

A wealth of information can be gained from using early stage drugs, experimental drugs and even failed efficacy drugs on terminally ill patients. This is the information Avacta are gathering. That they are on some clinical program to find a cure for cancer is being misconstrued by some private investors.

This is why AVA6000 has been on the longest Phase 1 clinical stage in medical history.

[bonzo] 21/3/2024 11:30

We have known it works for a long time. Sadly this has no impact on the share price.

[rajraj b] 21/3/2024 11:21

Also, if as you suggest, there is no evidence that AVA6000 is helping then why would these patients still be taking the drug? If they honestly thought it was doing nothing and their life has been extended purely because of chance they would not continue. It would not matter a jot if the drug was safe if it also didn't show some efficacy. It's working man.

[rajraj b] 21/3/2024 11:07

Like I said, some will say it's purely down to chance.

[pwhite73] 21/3/2024 11:05

Raj b - "These patients must feel they have been blessed."

There is no evidence the treatment has granted these patients additional years. If there was this RNS would be a BBC1 One O'clock news item.